Insider · CIK 0001862144

AULIN SHERRY

Reports to the SEC for 1 company · BURNABY, A1

sec.gov

Transactions

Companies

Filings

CIK

0001862144

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-12-18	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,334 sh	$9.44	+$88.1K	9,334
2024-12-18	XENEXenon Pharmaceuticals Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−2,135 sh	$41.28	−$88.1K	7,199
2024-12-18	XENEXenon Pharmaceuticals Inc.S Sale	Chief Financial Officer	SSale	−7,199 sh	$41.23	−$297K	0
2024-12-18	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+16K sh	$11.58	+$185K	16,000
2024-12-18	XENEXenon Pharmaceuticals Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,490 sh	$41.28	−$185K	11,510
2024-12-18	XENEXenon Pharmaceuticals Inc.S Sale	Chief Financial Officer	SSale	−11.5K sh	$41.19	−$474K	0
2024-12-18	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,334 sh	—	—	0
2024-12-18	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−16K sh	—	—	6,000
2024-03-11	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2023-03-10	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+120K sh	—	—	120,000
2022-09-02	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+32 sh	$7.49	+$239.68	9,032
2022-09-02	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,000 sh	$9.44	+$85K	9,000
2022-09-02	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,292 sh	—	—	0
2022-09-02	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,511 sh	—	—	0
2022-09-02	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+813 sh	$8.40	+$6,829.2	9,845
2022-09-02	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,292 sh	$3.10	+$7,105.2	12,137
2022-09-02	XENEXenon Pharmaceuticals Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,511 sh	$4.75	+$30.9K	18,648
2022-09-02	XENEXenon Pharmaceuticals Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−3,293 sh	$39.53	−$130K	15,355
2022-09-02	XENEXenon Pharmaceuticals Inc.S Sale	Chief Financial Officer	SSale	−15.4K sh	$39.57	−$608K	0
2022-09-02	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,000 sh	—	—	0
2022-09-02	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−32 sh	—	—	0
2022-09-02	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−813 sh	—	—	0
2022-03-10	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+125K sh	—	—	125,000
2021-06-03	XENEXenon Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Dec 194
AULIN SHERRY0000950170-24-138629
SEC(opens sec.gov)
Mar 124
AULIN SHERRY0000950170-24-030245
SEC(opens sec.gov)
Mar 144
AULIN SHERRY0001209191-23-018467
SEC(opens sec.gov)
Sep 74
AULIN SHERRY0001209191-22-049015
SEC(opens sec.gov)

Companies

Xenon Pharmaceuticals Inc.Chief Financial OfficerXENE

Address

200 - 3650 GILMORE WAY

BURNABY, A1, V5G 4W8